Browsing University of Galway Support Services by Author "Baccarani, M"
Now showing items 1-4 of 4
-
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase ii study
Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Radich, J P; Saglio, G; Hughes, T P; Martinelli, G; Kim, D-W; Novick, S; Gillis, K; Fan, X; Cortes, J; Baccarani, M; Kantarjian, H M (Springer Nature, 2012-07-05)Nilotinib (Tasigna) is a BCR-ABL1 tyrosine kinase inhibitor approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who are newly diagnosed or intolerant ... -
Nilotinib in patients with ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
le Coutre, P D; Giles, F J; Hochhaus, A; Apperley, J F; Ossenkoppele, G J; Blakesley, R; Shou, Y; Gallagher, N J; Baccarani, M; Cortes, J; Kantarjian, H M (Springer Nature, 2011-11-11)Nilotinib (Tasigna) is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase ... -
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
Giles, F J; Kantarjian, H M; le Coutre, P D; Baccarani, M; Mahon, F-X; Blakesley, R E; Gallagher, N J; Gillis, K; Goldberg, S L; Larson, R A; Hochhaus, A; Ottmann, O G (Springer Nature, 2011-12-13)Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or -intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400mg of nilotinib was ... -
Prediction of outcomes in patients with ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
Jabbour, E; le Coutre, P D; Cortes, J; Giles, F; Bhalla, K N; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Hughes, T P; Saglio, G; Radich, J P; Kim, D-W; Martinelli, G; Reynolds, J; Woodman, R C; Baccarani, M; Kantarjian, H M (Springer Nature, 2012-11-06)The purpose was to assess predictive factors for outcome in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) treated with nilotinib after imatinib failure. Imatinib-resistant and -intolerant patients ...